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Introduction
Approximately a third of patients undergoing cardiac surgery 
require blood products, more than in any other category of planned 
major surgery.[1,2] Transfused patients present with higher risk and 
experience increased mortality, both in the short and long-term.
[3,4,5] Transfusion may be necessary because of preoperative 
anaemia, blood loss, coagulopathy and haemodilution,[6,7] or 
because of haemodynamic instability,[1] the majority of patients 
receiving 2 units of blood.[7] Pre-existing anaemia is associated 
with other comorbidities and results in increased post-operative 
renal impairment as well as a higher stroke rate and mortality.[8] 
Prolonged intensive care stay exacerbates this situation leading 
to increased transfusion requirements.[9,10] Guidelines propose 
transfusion in unstable patients with a haemoglobin level below 7g/
dL,[11] but clinical decisions often overrule this recommendation, 
particularly in older patients.[12] There is evidence that transfusion 
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Abstract
Background
Transfusion is common after coronary bypass surgery. Transfused patients present with higher operative risk and increased hazard 
ratio for curtailed long-term survival. There is debate as to whether transfusion itself may further exacerbate late mortality. 
Methods
Long-term survival was studied in 2550 survivors following coronary revascularization in this retrospective, observational study. 
Kaplan-Meier survival curves were constructed to compare all transfused and non-transfused patients, as well as survival in 
propensity-matched transfused and non-transfused patients.
Results
Operative mortality was 1.05% (original cohort 2577). Maximum follow-up was 23 years (mean 11.8, median 12.4 years). 34.7% 
of patients received a transfusion (mean 2 units pack red blood cells). Baseline risk characteristics (age, female gender, small 
body habitus, risk stratification scoring, diabetes, hypertension and reduced stroke volume) operative parameters (urgency and no 
internal thoracic graft) as well as post-operative parameters (intensive care, hospital stay and ventilation time) and complications 
(haemorrhage, intra-aortic balloon, ventricular arrhythmias, prolonged inotropic support, atrial fibrillation, dialysis, doubling of 
creatinine and resternotomy) were higher in the transfused patients.  The long-term survival of these patients was significantly 
reduced when compared with that of non-transfused patients (log rank test p<0.001). When analyzed as a sole risk factor, transfusion 
was associated with reduced long-term survival (log rank test p<0.001) but when analyzed collectively with other risk factors, 
transfusion failed to demonstrate a causative effect (p=0.953). When propensity matched groups were compared (612 transfused 
versus 1222 non-transfused patients) long-term survival was similar (log rank test p=0.554). 
Conclusions 
Transfusion was required in higher risk patients undergoing coronary revascularization. Long-term survival was curtailed in this group 
but this was due to preoperative risk and not directly to transfusion. Transfusion was a predictor but not a cause of reduced long-term 
survival.
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in low-risk patients results in higher long-term mortality, and this 
practice should be avoided whenever possible.[13] Retrospective 
data shows improvement in some patients after transfusion, whilst 
in others with certain comorbidities, the outcome is worse.[14] 
Moreover, the loose temporal relationship between transfusion 
and the onset of complications or death makes for an uncertain 
causative role,[15] particularly in the setting of poorer outcomes.
[16,17]
Patients and methods
This retrospective, observational, cohort study was conducted 
using our dedicated coronary surgery database and included all 
consecutive patients undergoing solitary coronary artery bypass 
grafting utilizing cardiopulmonary bypass in a single-surgeon 
practice between 1st April 1995 and 31st December 2016. 
Data was collected prospectively and analyzed in December 
2018 (observation time 2 to 23.5 years) and included patient 
demographics, operative urgency, risk scores, cardiac indices, 
surgery-, anaesthesia- and intensive care-related data, and in-
hospital length of stay and complications (table 1). Transfusion-
related data was recorded on anaesthesia and intensive care 
forms. All data was completed and validated at the point of the 
patient’s discharge from hospital, and further systematically 
validated on a yearly basis. The primary endpoint was all-cause 
mortality during the follow-up period. Data pertaining to date of 
death was obtained from the National Statistics Office, using 
a unique personal identity number assigned to every patient. 
Patients, who died within 30 days, or while still in hospital after 
surgery, were excluded from the study.
Patients were risk-stratified by Parsonnet score (from 1995) as 
well as by additive (after 2000) and logistic EuroSCORE (after 
2006). All complications were recorded in real time and classified 
according to organ-system. Data collection included incidence 
of perioperative myocardial infarction, arrhythmia, intra-aortic 
balloon counter-pulsation and permanent pacemaker use, 
transient ischaemic attack, stroke, temporary renal impairment, 
dialysis, gastrointestinal haemorrhage or perforation and 
resternotomy for tamponade or haemorrhage. Ventilation time, 
blood volume loss and transfusion, and inotropic support were 
also recorded.
Packed red blood cells, fresh frozen plasma and platelet 
transfusions were prescribed by the attending surgeon and 
anaesthetist. Indications were based on haemodynamic data, 
blood loss, haemoglobin and haematocrit levels and comorbid 
conditions. Thromboelastometry-guided therapy supplemented 
routine activated clotting time, international normalized ratio 
and activated partial thromboplastin time, platelet counts and 
fibrinogen levels where indicated. A lower target haemoglobin 
level was accepted in younger patients. The decision to transfuse 
was also guided by the clinical picture.
Antiplatelet drugs were stopped 5 days before routine surgery when 
logistically feasible, but aspirin and/or heparin were administered 
until surgery in acute coronary syndrome, and in urgent or 
emergency cases. All patients underwent cardiopulmonary bypass 
with surface-modified tubing and membrane oxygenator at 
normothermia and myocardial protection was with antegrade cold 
blood cardioplegia. Tranexamic acid was used routinely whereas 
aprotinin was only administered rarely and for excess blood loss.
Table 1.Risk indicators in transfused and non-transfused 
patients
parameter
transfused 
n%/m(SD) 
n:886
not transfused 
n%/m(SD) 
n:1664
p value
age 64.89 (8.84) 61.39 (8.72) <0.001
female gender 296 (33.4%) 204 (12.3%) <0.001
height 1.60 (0.10) 1.63 (0.09) <0.001
weight 74.40 (13.16) 79.36 (13.22) <0.001
body surface area 1.77 (0.19) 1.85 (0.18) <0.001
body mass index 29.15 (4.41) 29.68 (4.24) 0.005
Parsonnet score 7.96 (5.79) 5.35 (4.66) <0.001
additive EuroSCORE 3.38 (2.23) 2.30 (1.93) <0.001
logistic EuroSCORE 3.37 (4.01) 2.33 (1.95) <0.001
diabetes 260 (29.3%) 353 (21.2%) <0.001
hypertension 428 (48.3%) 621 (37.3%) <0.001
ejection fraction 71.23 (13.49) 72.15 (12.96) 0.146
stroke volume 87.38 (28.60) 93.55 (28.71) <0.001
urgent 236 (26.6%) 354 (21.3%) 0.002
emergency 20 (2.3%) 12 (0.7%) 0.001
single coronary bypass 16 (1.8%) 38 (2.3%) 0.425
double coronary bypass 203 (22.9%) 361 (21.7%) 0.481
triple coronary bypass 400 (45.1%) 788 (47.4%) 0.287
quadruple coronary bypass 234 (26.4%) 401 (24.1%) 0.199
quintuple coronary bypass 32 (3.6%) 76 (4.6%) 0.254
no internal thoracic graft 32 (3.6%) 31 (1.9%) 0.007
ischaemic time 29.89 (9.44) 30.20 (8.71) 0.424
bypass time 57.74 (16.53) 56.69 (16.01) 0.126
intensive care (dy) 1.06 (0.38) 1.02 (0.42) 0.023
high dependency (dy) 1.70 (4.37) 0.84 (2.15) <0.001
ward (dy) 3.16 (2.60) 2.80 (2.18) <0.001
ventilation (hr) 9.23 (7.94) 7.43 (5.79) <0.001
ventilation >24hr 20 (2.3%) 14 (0.8%) 0.003
haemorrhage (ml) 620.8 (347.9) 491.7 (169.6) <0.001
intra-aortic balloon 46 (5.2%) 17 (1.0%) <0.001
permanent pacemaker 3 (0.3%) 3 (0.2%) 0.432
ventricular arrhythmia 19 (2.1%) 18 (1.1%) 0.033
inotropic support >24hr 309 (34.9%) 269 (16.2%) <0.001
atrial fibrillation 159 (17.9%) 237 (14.2%) 0.014
atrial flutter 10 (1.1%) 20 (1.2%) 0.870
dialysis 22 (2.5%) 2 (0.1%) <0.001
doubling of creatinine 53 (6.0%) 18 (1.1%) <0.001
gastric haemorrhage 3 (0.3%) 5 (0.3%) 0.870
stroke 7 (0.8%) 12 (0.7%) 0.847
transient ischaemic attack 8 (0.9%) 8 (0.5%) 0.199
resternotomy 8 (0.9%) 5 (0.3%) 0.042
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Statistical Methods 
Kaplan-Meier survival curves were constructed to compare all 
transfused and non-transfused patients, as well as survival in 
propensity matched transfused and non-transfused patients. 
Risk indicators in the two groups were compared using the chi-
squared test for categorical variables and the Student’s t-test 
for continuous variables. Cox regression analysis was used to 
calculate hazard ratios for curtailed long-term survival.
Results
A total of 2550 patients (886 transfused, 1664 not transfused) were 
included after elimination of 27 patients who died perioperatively 
(mortality 1.05%). Risk indicators were significantly higher in 
the transfused patients. These included age, female gender, 
small body habitus, Parsonnet score, additive EuroSCORE 
and logistic EuroSCORE, diabetes, hypertension, lower stroke 
volume, operative urgency, no internal thoracic graft, intensive 
care, hospital stay and ventilation time, haemorrhage, intra-aortic 
balloon, ventricular arrhythmias, prolonged inotropic support, 
atrial fibrillation, dialysis, doubling of creatinine and resternotomy 
(table 1). 
The transfused patients experienced more post-operative 
haemorrhage (620.8±347.9ml versus 491.7±169.6ml, p<0.001) 
and a higher incidence of excessive haemorrhage (9.9% versus 
1.0% >1L p<0.001, 2.7% versus 0.06% >1.5L, p<0.001). Of the 
transfused patients, 45.5% received 1 unit, 34.6% 2 units, 15.1% 
3-4 units, 2.9% 5-6 units and 1.9% over 6 units. There was a 
significant positive correlation between the haemorrhage volume 
and the amount transfused (figure 1).
The hazard ratio for each parameter was calculated by Cox 
Regression analysis (table 2). All explanatory variables with p values 
less than the 0.05 level of significance were significant predictors 
of survival duration.  When the explanatory variables were analyzed 
individually, twenty-four variables were found to be significant 
predictors of survival duration; however when the variables were 
analyzed collectively these predictors (except Parsonnet score 
Table 2. Cox-Regression analysis relating survival duration to 
each predictor individually 
parameter  n%/m(SD) Hazard Ratio
(95%) CI of 
HR
p 
value
transfused 886 (34.7%) 1.728 (1.483 – 2.013) <0.001
age 62.61 (8.917) 1.081 (1.071 – 1.091) <0.001
female gender 500 (19.6%) 1.187 (0.991 – 1.422) 0.062
height 1.620 (0.091) 0.085 (0.035 – 0.203) <0.001
weight 77.59 (13.41) 0.988 (0.982 – 0.995) <0.001
body surface area 1.822 (0.188) 0.327 (0.207 – 0.514) <0.001
body mass index 29.49 (4.305) 1.002 (0.983 – 1.022) 0.836
Parsonnet score 6.258 (5.226) 1.111 (1.098 – 1.124) <0.001
additive EuroSCORE 2.674 (2.104) 1.263 (1.226 – 1.301) <0.001
logistic EuroSCORE 2.711 (2.923) 1.094 (1.053 – 1.137) <0.001
diabetes 613 (24.0%) 1.555 (1.289 – 1.874) <0.001
hypertension 1049 (41.1%) 1.087 (0.912 – 1.295) 0.354
ejection fraction 71.81 (13.17) 0.991 (0.984 – 0.998) 0.008
stroke volume 91.25 (28.81) 0.997 (0.993 – 1.000) 0.047
urgent 590 (23.1%) 1.226 (1.026 – 1.466) 0.025
emergency 32 (1.3%) 0.914 (0.455 – 1.835) 0.800
single coronary 
bypass 54 (2.1%) 0.785 (0.432 – 1.424) 0.426
double coronary 
bypass 564 (22.1%) 1.300 (1.088 – 1.553) 0.004
triple coronary 
bypass 1188 (46.6%) 0.981 (0.842 – 1.142) 0.800
quadruple coronary 
bypass 635 (24.9%) 0.844 (0.708 – 1.006) 0.058
quintuple coronary 
bypass 108 (4.2%) 0.928 (0.647 – 1.331) 0.685
no internal thoracic 
graft 63 (2.5%) 1.393 (0.860 – 2.255) 0.178
ischaemic time 30.09 (8.966) 0.994 (0.985 – 1.002) 0.143
bypass time 57.05 (16.20) 0.998 (0.993 – 1.002) 0.293
intensive care (dy) 1.036 (0.409) 1.491 (1.315 – 1.690) <0.001
high dependency (dy) 1.154 (3.184) 1.060 (1.047 – 1.074) <0.001
ward (dy) 2.925 (2.337) 1.077 (1.057 – 1.097) <0.001
ventilation (hr) 8.052 (6.668) 1.020 (1.013 – 1.028) <0.001
ventilation >24hr 34 (1.3%) 1.508 (0.808 – 2.818) 0.197
haemorrhage (ml) 536.6 (254.1) 1.000 (1.000 – 1.000) 0.899
intra-aortic balloon 63 (2.5%) 1.617 (1.036 – 2.523) 0.034
permanent 
pacemaker 6 (0.2%) 7.156 (3.202 – 15.99) <0.001
ventricular arrhythmia 37 (1.5%) 1.754 (0.991 – 3.105) 0.054
inotropic support 
>24hr 578 (22.7%) 2.213 (1.880 – 2.604) <0.001
atrial fibrillation 396 (15.5%) 1.409 (1.148 – 1.729) 0.001
atrial flutter 30 (1.2%) 1.352 (0.724 – 2.524) 0.344
dialysis 24 (0.9%) 4.000 (2.136 – 7.491) <0.001
doubling of creatinine 71 (2.8%) 3.324 (2.350 – 4.703) <0.001
gastric haemorrhage 8 (0.3%) 1.285 (0.321 – 5.152) 0.723
stroke 19 (0.7%) 1.147 (0.476 – 2.764) 0.761
transient ischaemic 
attack 16 (0.6%) 5.109 (2.882 – 9.058) <0.001
resternotomy 13 (0.5%) 1.638 (0.613 – 4.378) 0.325Figure 1 Correlation between haemorrhage volume and amount 
transfused
Correlation between amount transfused and haemorrhage 
volume
Pearson correlation 0.433
p value 0.000
sample size 886
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and double coronary bypass) were not significant since their p 
values exceeded the level of significance of 0.05. Using a forward 
procedure, three predictors were found to be significant (table 
3). The parsimonious survival model, that analyzed all the 
explanatory variables collectively and retained the significant 
predictors, identified Parsonnet score as the strongest predictor 
of survival duration, followed by doubling of creatinine and 
double coronary bypass. 
When analyzed as a sole risk factor, transfusion was associated 
with reduced long-term survival (log rank test p<0.001) but when 
analyzed collectively with other risk factors, transfusion failed to 
demonstrate a causative effect (p=0.953).
The survival probability of transfused patients was significantly 
worse (p <0.001), (figure 2). This difference was present from the 
early postoperative phase and increased with time (44% versus 
62% 19-year survival).
274 patients (30.9%) were deleted from the transfused group 
(886-274=612) and 442 patients (26.6%) from the non-transfused 
group (1664-442=1222) in order to achieve propensity matching 
for 18 important risk factors. The deleted patients (table 5) 
included high-risk patients from the transfused group and low-risk 
patients from the not-transfused group, with the former having 
24 risk factors that were significantly worse than the latter. The 
resultant propensity-matched groups were comparable for age, 
gender, height, additive EuroSCORE and logistic EuroSCORE, 
ejection fraction and stroke volume, urgency, no internal thoracic 
graft, ischaemic time, permanent pacemaker, ventricular 
arrhythmia, atrial fibrillation and flutter, gastric haemorrhage, 
stroke, transient ischemic attack and resternotomy (table 4). The 
survival probability (figure 3) and the cumulative hazard (figure 
4) of the propensity-matched transfused and non-transfused 
patients were similar (p =0.554).
Discussion
Patients who died perioperatively were excluded from this study 
because common causes of hospital death such as cardiogenic 
shock and sepsis could overshadow the influence of transfusion 
as a contributory factor.[18] 
Transfusion of 1 to 2 units of packed red blood cells has been 
shown to increase perioperative morbidity [19] and mortality,[7] 
as well as mortality in the medium term.[20] There is evidence 
to suggest that preventing a low haemoglobin immediately after 
bypass, and its attendant renal complications, may be preferable 
to correcting it with a transfusion. However it is difficult to 
determine whether the anaemia or the transfusion is the cause of 
increased early morbidity.[21]  
When haemorrhage results in severe anaemia with organ 
dysfunction due to reduced oxygen-carrying capacity, transfusion 
can correct the situation. Transfusion has been postulated to be 
detrimental by way of its depleted 2,3 Diphosphoglycerate, shifting 
the oxygen dissociation curve leftwards and reducing oxygen 
delivery. Transfusion also raises cytokine levels, increasing the 
already high inflammatory state after cardiopulmonary bypass.
[22,23]
Table 3. Parsimonious survival model using a forward 
procedure
parameter Wald df p value Hazard Ratio
95% 
lower 
limit
95% 
upper 
limit
Parsonnet score 65.760 1 0.000 1.149 1.111 1.189
doubling of 
creatinine 10.333 1 0.001 3.705 1.667 8.232
double coronary 
bypass 4.487 1 0.037 1.730 1.042 2.870
Table 4. Risk indicators in propensity-matched transfused and 
non-transfused patients
parameter
transfused 
n%/m(SD) 
n:612
not 
transfused 
n%/m(SD) 
n:1222
p value
age 62.85 (8.56) 62.89 (8.95) 0.924
female gender 89 (14.5%) 179 (14.6%) 0.995
height 1.62 (0.09) 1.63 (0.09) 0.397
additive EuroSCORE 2.71 (1.92) 2.70 (1.86) 0.973
logistic EuroSCORE 2.56 (2.81) 2.67 (1.93) 0.621
ejection fraction 70.92 (13.20) 71.88 (13.22) 0.201
stroke volume 89.57 (29.30) 91.83 (28.08) 0.166
urgent 142 (23.2%) 292 (23.7%) 0.798
no internal thoracic graft 22 (3.6%) 26 (2.1%) 0.060
ischaemic time 30.65 (9.76) 30.10 (8.58) 0.220
permanent pacemaker 1 (0.2%) 2 (0.2%) 0.997
ventricular arrhythmia 14 (2.3%) 14 (1.1%) 0.545
atrial fibrillation 96 (15.7%) 192 (15.6%) 0.966
atrial flutter 9 (1.5%) 14 (1.1%) 0.870
gastric haemorrhage 3 (0.5%) 4 (0.3%) 0.588
stroke 5 (0.8%) 9 (0.7%) 0.843
transient ischaemic 
attack 4 (0.7%) 8 (0.7%) 0.994
resternotomy 6 (1.0%) 4 (0.3%) 0.071
Figure 2 Kaplan-Meier survival curves in transfused and non-
transfused patients
Overall Comparisons
Chi-Square df p value
Log Rank (Mantel-Cox) 60.677 1 <0.001
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Previous studies have shown little [24] or no [25] effect of 
transfusion on long-term survival whereas a study, by Jakobsen et 
al, demonstrated a strong correlation between transfusion in low-
risk patients (EuroSCORE 0-4) and reduced long-term survival.
[26] A possible mechanism proposed is immune modulation 
following a transfusion.[27] 54.7% of our transfused patients and 
75.7% of our non-transfused patients were in a comparable risk 
category but our results are at variance with this study, which 
had a maximum follow-up of 12 years and also included patients 
undergoing valve replacement. Moreover, in our propensity-
matched groups the additive EuroSCORE was equivalent at a 
mean of 2.7 and long-term survival was similar. 
Urgent and emergency operations were significantly more 
frequent (p=0.002 and p=0.001 respectively) in the transfused 
group. These patients received aspirin and/or Heparin 
immediately prior to surgery, making them more likely to bleed 
excessively postoperatively, and to require transfusion. This risk 
factor was present equally in the propensity-matched groups. 
The strong correlation between the amount of blood transfused 
and the postoperative haemorrhage volume suggests that the 
clinical decision to transfuse was justified. Reassessment of the 
clinical situation after the first unit resulted in a lesser amount 
transfused (80.1% received 1-2 units).   
Although total postoperative stay was higher in transfused 
patients (mean 5.92 versus 4.66) this still represented a short 
hospital stay, taking into consideration the higher mean age (64.9 
versus 61.4) and the fact that all patients were discharged to their 
home. In these patients transfusion may have helped expedite 
their recovery and mitigate an even longer hospital stay.
There is still no consensus regarding transfusion in critically ill 
patients undergoing coronary artery surgery. Practices vary widely 
in different centres, but transfusions tend to be more frequent in 
elderly, female patients receiving anti-platelet medications.[28] 
A life-saving transfusion must be weighed up against possible 
infection, lung-injury, circulatory overload, and possible adverse 
long-term outcomes.[29] Withholding transfusion when the 
Table 5. Risk indicators in transfused and non-transfused 
deleted patients
parameter
transfused 
n%/m(SD) 
n:274
not transfused 
n%/m(SD) n:442
p 
value
age 68.9 (7.917) 57.10 (6.543) <0.001
female 194 (70.8%) 25 (5.7%) <0.001
height 1.54 (0.092) 1.66 (0.079) <0.001
weight 69.88 (11.277) 81.48 (13.094) <0.001
body surface area 1.68 (0.160) 1.89 (0.176) <0.001
body mass index 29.41 (4.549) 29.615 (4.042) 0.554
Parsonnet score 10.85 (6.135) 3.85 (3.576) <0.001
additive EuroSCORE 4.61 (2.264) 1.15 (1.663) <0.001
logistic EuroSCORE 5.71 (5.883) 1.66 (2.123) <0.001
diabetes 73 (26.6%) 98 (22.2%) 0.173
hypertension 126 (46.0%) 162 (36.7%) 0.013
ejection fraction 71.59 (14.139) 73.14 (11.794) 0.190
stroke volume 83.98 (27.017) 98.25 (29.385) <0.001
urgent 91 (33.2%) 68 (15.4%) <0.001
emergency 11 (4.0%) 5 (1.1%) 0.011
single coronary bypass 5 (1.8%) 11 (2.5%) 0.559
double coronary bypass 70 (25.5%) 92 (20.8%) 0.141
triple coronary bypass 139 (50.7%) 196 (44.3%) 0.096
quadruple coronary 
bypass 57 (20.8%) 118 (26.7%) 0.074
quintuple coronary 
bypass 2 (0.7%) 25 (5.7%) 0.001
no internal thoracic graft 10 (3.6%) 6 (1.4%) 0.044
ischaemic time 28.20 (8.476) 30.51 (8.916) 0.001
bypass time 54.78 (15.257) 57.18 (16.445) 0.054
intensive care (dy) 1.04 (0.294) 1.00 (0.067) 0.024
high dependency (dy) 1.47 (2.162) 0.67 (1.106) <0.001
ward (dy) 3.45 (2.809) 2.60 (1.296) <0.001
ventilation (hr) 8.80 (5.406) 6.81 (3.267) <0.001
haemorrhage (ml) 542.26 (331.383) 500.64 (160.124) 0.053
intra-aortic balloon 16 (5.8%) 4 (0.9%) <0.001
permanent pacemaker 2 (0.7%) 1 (0.2%) 0.311
ventricular arrhythmia 4 (1.5%) 4 (0.9%) 0.492
inotropic support >24hr 93 (33.9%) 55 (12.4%) <0.001
atrial fibrillation 63 (23.0%) 46 (10.4%) <0.001
atrial flutter 3 (1.1%) 5 (1.1%) 0.964
ventilation >24hr 4 (1.5%) 1 (0.2%) 0.054
dialysis 7 (2.6%) 0 (0.0%) 0.001
doubling of creatinine 15 (5.5%) 3 (0.7%) <0.001
gastric haemorrhage 0 (0.0%) 1 (0.2%) 0.431
stroke 1 (0.4%) 3 (0.7%) 0.584
transient ischaemic 
attack 4 (1.5%) 0 (0.0%) 0.011
resternotomy 2 (0.7%) 1 (0.2%) 0.311
Figure 3 Survival probability of the propensity-matched 
transfused and non-transfused patients
Overall Comparisons
Chi-Square df p value
Log Rank (Mantel-Cox) 0.350 1 0.554
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haematocrit is above 24% has not been shown to increase early 
morbidity and mortality.[30] A lack of clear evidence on the benefits 
of transfusion should promote a restrictive transfusion policy.
Limitations
The retrospective nature of this observational study necessarily 
limits the proof of a causal relationship between transfusion and 
poorer outcomes, especially in the long-term. 
Although transfusion was not a predictor of long-term survival, 
other confounders that were either not measured, or that were 
not matched by propensity scoring, may have influenced 
survival. The severity of the clinical presentation with high-risk 
patients and urgent operations is more likely to affect outcomes 
or to overshadow the role of transfusion. 
Propensity score analysis was employed to reduce bias in this 
observational study, as randomization into two treatment groups 
was not possible. Propensity matching was only achieved 
for 18 out of 41 risk variables as further matching would have 
significantly reduced the size of both groups, rendering them 
unrepresentative of the original cohorts.
Conclusion
Blood transfusion can save lives when used appropriately. This 
study shows that long-term survival was curtailed in transfused 
patients but this was due to preoperative risk and not directly to 
transfusion, which was a significant predictor but not a cause 
of reduced long-term survival. Controversy still exists regarding 
the causal nature of transfusion and long-term outcomes and it 
would be prudent to use blood products with greater vigilance. 
Further research is required to clarify the problem.
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